drugset / Trial / NCT03473236
Phase 1A Safety Trial of Inhaled PK10571 (GB002)
Phase 1
Completed
66 enrolled
Gossamer Bio, Inc.
Pulmokine Inc. · collabWorldwide Clinical Trials · collab
RandomizedSequentialQuadruple-blindTreatment
Summary
This is a phase 1A randomized double blind placebo controlled single ascending dose and multiple ascending dose trial of inhaled PK10571 (GB002) in healthy adult subjects.
Timeline
- Start
- 2017-09-06
- Primary completion
- 2018-12-03
- Completion
- 2018-12-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Seralutinib | Peptide | — | Inhaled |
Indications
No indication recorded.